🇪🇺 LCP-tacrolimus in European Union

EMA authorised LCP-tacrolimus on 18 July 2014

Marketing authorisation

EMA — authorised 18 July 2014

  • Application: EMEA/H/C/002655
  • Marketing authorisation holder: Chiesi Farmaceutici S.p.A.
  • Local brand name: Envarsus
  • Indication: Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
  • Status: approved

Read official source →

Other Immunology approved in European Union

Frequently asked questions

Is LCP-tacrolimus approved in European Union?

Yes. EMA authorised it on 18 July 2014.

Who is the marketing authorisation holder for LCP-tacrolimus in European Union?

Chiesi Farmaceutici S.p.A. holds the EU marketing authorisation.